AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19885409
Drug: Fluoride treatment
RxNorm normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride treatment (FTB)
Trial: 19885409
Drug: Titanium dioxide
RxNorm normalized name: Titanium Dioxide
DrugBank: Titanium dioxide (DB09536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titanium dioxide grit-blasted (TB) implants
Trial: 11350556
Drug: Epinephrine irrigation
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine irrigation (40‐120 mL of 1:1,000,000 epinephrine)
Trial: 1841833
Drug: High-dose bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose bovine surfactant (100 mg/kg birth weight)
Trial: 1841833
Drug: Low-dose bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose bovine surfactant (50 mg/kg birth weight)
Trial: 3300375
Drug: Bromocriptine, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine, 2.5 mg twice daily
Trial: 31306084
Drug: RTS,S/AS01 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 with dihydroartemisinin-piperaquine plus a single low dose primaquine
Trial: 31306084
Drug: RTS,S/AS01 without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 without antimalarial drugs
Trial: 31306084
Drug: RTS,S/AS01 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 with and without antimalarial drugs
Trial: 25327812
Drug: Nemonoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (500 mg) + Antacid (318 mg Al(3+) and 496 mg Mg(2+))
Trial: 25327812
Drug: Nemonoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (500 mg) + Antacid (4 hours after)
Trial: 25327812
Drug: Nemonoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (500 mg) + Antacid (2 hours before)
Trial: 25327812
Drug: Nemonoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (500 mg) + Ferrous sulfate (60 mg Fe(2+))
Trial: 25327812
Drug: Nemonoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (500 mg) + Calcium carbonate (600 mg Ca(2+))
Trial: 25327812
Drug: Nemonoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (500 mg) alone
Trial: 20737683
Drug: INFLUVIR vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INFLUVIR vaccine administered intranasally
Trial: 20737683
Drug: PANDEFLU vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PANDEFLU vaccine administered intramuscularly
Trial: 10714789
Drug: Newer antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer antibiotics (macrolides and quinolones)
Trial: 10714789
Drug: Conventional antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antimicrobial therapy (beta-lactam therapy)
Trial: 1867232
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg/day
Trial: 1867232
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg/day
Trial: 7572686
Drug: Lovastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20-40 mg/day)
Trial: 1831006
Drug: Lovastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (80 mg/day)
Trial: 6861303
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (daily prescribed physical exercise for 60 days)
Trial: 29746823
Drug: Behavior-change intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavior-change intervention (weekly 30-minute telephone sessions for 12 weeks)
Trial: 23706899
Drug: Venlafaxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine treatment
Trial: 17180128
Drug: Test solution
RxNorm normalized name: Candin Skin Test Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solution (sterile, isotonic solution patterned after human amniotic fluid), 2.5 ml/kg every 3 hours via OG/NG tube for up to 7 days.
Trial: 17180128
Drug: Sham administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham administration (control), every 3 hours via OG/NG tube for up to 7 days.
Trial: 17180128
Drug: Test solution
RxNorm normalized name: Candin Skin Test Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solution (compared to sham),
Trial: 15677431
Drug: Prolactin-elevating antipsychotics
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolactin-elevating antipsychotics (control)
Trial: 2943811
Drug: Yeast-derived recombinant
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived recombinant hepatitis B vaccine
Trial: 25230741
Drug: Catechin-rich green
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catechin-rich green tea (615 mg/350 ml)
Trial: 25230741
Drug: Placebo (92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (92 mg/350 ml)
Trial: 11703992
Drug: Azimilide 100
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 100 mg/day
Trial: 11703992
Drug: Azimilide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide (100 and 125 mg/day)
Trial: 9627377
Drug: Tall oil
RxNorm normalized name: TALL OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tall oil phytosterols (21.2 mg/kg body weight/d)
Trial: 2778240
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (20 mg three times daily)
Trial: 21963936
Drug: HIV-1 gp120/NefTat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 gp120/NefTat vaccine with AS02A adjuvant
Trial: 19948278
Drug: Verteporfin photodynamic
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin photodynamic therapy (VPDT)
Trial: 11238754
Drug: 750 mL
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mL red wine
Trial: 11238754
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g fried onions
Trial: 11238754
Drug: 375 mL
RxNorm normalized name: isopropyl alcohol 0.0375 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mL black tea
Trial: 15338492
Drug: Pamidronate 45
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 45 mg
Trial: 2179802
Drug: Chlorhexidine mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthrinse (0.12% chlorhexidine digluconate, 15 ml, three times a day)
Trial: 408116
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 100 mg iron as ferrous glycocoll sulphate in micropellets
Trial: 408116
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 50 mg iron as ferrous glycocoll sulphate in micropellets
Trial: 408116
Drug: Iron preparation
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparation given at the end of breakfast
Trial: 408116
Drug: Fasting absorption
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting absorption measurement
Trial: 28073036
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate solution 800mL the night before and 400mL 2h prior to operation
Trial: 28073036
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate solution
Trial: 25957793
Drug: Daily lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lipid-based nutrient supplement
Trial: 21801246
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of L. reuteri in stool in the first week of life
Trial: 19905885
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (Exubera)
Trial: 10589362
Drug: Infliximab in
RxNorm normalized name: infliximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab in combination with methotrexate (MTX)
Trial: 10589362
Drug: Infliximab with
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab with high-dose MTX
Trial: 8735175
Drug: Doxazosin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (dose 2 to 16 mg)
Trial: 8735175
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) (dose 25 to 50 mg)
Trial: 1929337
Drug: Ampicillin-sulbactam (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam (750 mg orally twice daily for 10 days)
Trial: 1929337
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g intramuscularly) and probenecid (1 g orally), followed by doxycycline (100 mg orally twice daily for 10 days)
Trial: 29323932
Drug: BrAC 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BrAC 0.08 g/210 L
Trial: 29323932
Drug: BrAC 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BrAC 0.10 g/210 L
Trial: 29323932
Drug: BrAC 0.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BrAC 0.00 g/210 L
Trial: 26354331
Drug: Physicians' choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians' choice therapy (standard chemo‐ or endocrine therapy) with or without additional HER2‐targeted therapy with lapatinib (DETECT III trial)
Trial: 26354331
Drug: Everolimus and
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus and standard endocrine therapy (DETECT IVa)
Trial: 26354331
Drug: Dual HER2-targeted
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dual HER2-targeted therapy (trastuzumab plus pertuzumab) plus either endocrine or chemotherapy (DETECT V/CHEVENDO trial)
Trial: 18755361
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment combining a vitamin D derivative and a strong glucocorticoid
Trial: 18755361
Drug: Long-established pharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-established pharmaceuticals (cignolin, tar preparations, glucocorticoids)
Trial: 18755361
Drug: Newer topical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer topical agents (vitamin A and D derivatives)
Trial: 18755361
Drug: Agents directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents directed at tumor necrosis factor alpha, Toll-like receptors, and neutrophils
Trial: 14501738
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose human chorionic gonadotropin (HCG)
Trial: 31547939
Drug: Oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-acetylcysteine
Trial: 9120179
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin plus oral N-acetylcysteine
Trial: 8468108
Drug: ITF 282
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 282 (60 mg iron/day, 2 tablets)
Trial: 8468108
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (105 mg iron/day, 1 tablet)
Trial: 31620931
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus trastuzumab and chemotherapy
Trial: 26473300
Drug: Nitazoxanide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (500 mg twice daily)
Trial: 9600579
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg oral m-CPP
Trial: 6439699
Drug: Mixed beam
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed beam radiation therapy
Trial: 6350243
Drug: Photon control
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon control treatment
Trial: 29176402
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day hydrocortisone
Trial: 29176402
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day hydrocortisone
Trial: 26335669
Drug: Kineflex‐L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kineflex‐L
Trial: 26335669
Drug: Serum ion
RxNorm normalized name: Sulfate ion
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum ion analysis (Kineflex‐L subgroup)
Trial: 20153030
Drug: Medium-dose extract
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose extract (4.8 microg Amb a 1/d)
Trial: 20153030
Drug: High-dose extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose extract (48 microg Amb a 1/d)
Trial: 18589036
Drug: 500‐mL water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mL water preload
Trial: 15947768
Drug: TEE-guided cardioversion
RxNorm normalized name: ADAPTER,VALVED TEE 22MM #1009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEE-guided cardioversion with oral anticoagulation
Trial: 10805055
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg/day for 3 months)
Trial: 8651963
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) at 3 mg/kg/day
Trial: 1299483
Drug: 1 gm
RxNorm normalized name: Ifex 1 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gm of tribasic sodium phosphate four times daily for 3 days
Trial: 1299483
Drug: Glucose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose placebo four times daily for 3 days
Trial: 27494570
Drug: LNG-IUS 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-IUS 8 (average levonorgestrel release rate approximately 8 μg/24 h over the first year, total content 13.5 mg)
Trial: 27494570
Drug: EE/DRSP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/DRSP (30 μg ethinyl estradiol/3 mg drospirenone)
Trial: 19995925
Drug: Raltegravir-based highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir-based highly active antiretroviral therapy (HAART)
Trial: 17599884
Drug: Hypothermic cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic cardioplegic solution (HCS)
Trial: 16239366
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium (25 mg)
Trial: 16239366
Drug: Perindopril erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril erbumine (2 mg)
Trial: 2668129
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of SMS 201-995 at 25 micrograms/h
Trial: 2668129
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of SMS 201-995 at 50 micrograms every 12 hours
Trial: 2668129
Drug: Subcutaneous SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous SMS 201-995 administered by patients at home during open follow-up study
Trial: 7240437
Drug: Aspirin (975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (975 mg administered four times a day, total daily dose 3.9 Gm)
Trial: 7240437
Drug: Oxaprozin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaprozin (1200 mg once a day)
Trial: 28474783
Drug: Peri-implant probing
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-implant probing
Trial: 31325382
Drug: Implant design
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant design (with/without platform switching)
Trial: 15850497
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of oral glucosamine sulphate (GS)
Trial: 12456918
Drug: Bladder augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder augmentation using intestinal segments in myelomeningocele patients
Trial: 12456918
Drug: Bladder augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder augmentation in bladder exstrophy patients
Trial: 10839045
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of educative‐supportive system of care and behavior modification (Condition 1)
Trial: 1892197
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic
Trial: 31857780
Drug: Modified bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified bismuth-containing quadruple therapy (mBCQT) for 2 weeks
Trial: 31857780
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (CT) for 2 weeks
Trial: 31857780
Drug: Modified bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified bismuth-containing quadruple therapy (mBCQT)
Trial: 25395221
Drug: In-Home Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting (n = 47)
Trial: 24268907
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid gel
Trial: 22166954
Drug: Sucromalt (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucromalt (30 g)
Trial: 22166954
Drug: Inulin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (15 g)
Trial: 16697124
Drug: Amantadine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (300 mg/day)
Trial: 19756426
Drug: Misoprostol suppositories
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol suppositories
Trial: 14656921
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (ACEI) group, n=19
Trial: 10626195
Drug: 5-fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (500 mg/m2/day by continuous intravenous infusion for 5 days) combined with cisplatin (80 mg/m2 intravenously on the 1st day)
Trial: 2041004
Drug: Flumazenil (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.01 mg/kg)
Trial: 25780462
Drug: Doxapram (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (1 mg/kg)
Trial: 24659140
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stable medication only)
Trial: 18345521
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (cetrorelix acetate 0.25 mg) administered when follicles reached > or =14 mm
Trial: 18345521
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (leuprolide acetate) in a long protocol
Trial: 10027580
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (tinzaparin) for 3 weeks
Trial: 1799911
Drug: Nitro-Dur Transdermal
RxNorm normalized name: Nitro-Dur Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitro-Dur Transdermal Infusion System
Trial: 1799911
Drug: Transderm-Nitro Transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transderm-Nitro Transdermal Therapeutic System
Trial: 6230209
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate - 50 mg b.i.d.